Contract Pharmaceutical Fermentation Services Market

Contract Pharmaceutical Fermentation Services Market Forecast and Outlook (2025-2035)

The global contract pharmaceutical fermentation services market is valued at USD 16.0 billion in 2025 and is slated to reach USD 34.6 billion by 2035, recording an absolute increase of USD 18.6 billion over the forecast period. This translates into a total growth of 116.3%, with the market forecast to expand at a compound annual growth rate (CAGR) of 7.8% between 2025 and 2035.

The overall market size is expected to grow by nearly 2.2X during the same period, supported by increasing biopharmaceutical development, growing outsourcing trends, and rising adoption of specialized manufacturing services across diverse drug development and commercial production applications.

Quick Stats for Contract Pharmaceutical Fermentation Services Market

• Contract Pharmaceutical Fermentation Services Market Value (2025): USD 16.0 billion
• Contract Pharmaceutical Fermentation Services Market Forecast Value (2035): USD 34.6 billion
• Contract Pharmaceutical Fermentation Services Market Forecast CAGR: 7.8%
• Leading Scale in Contract Pharmaceutical Fermentation Services Market: Commercial GMP (52.0%)
• Key Growth Regions in Contract Pharmaceutical Fermentation Services Market: North America, Europe, and Asia Pacific

• Key Players in Contract Pharmaceutical Fermentation Services Market: Lonza, Thermo Fisher, Fujifilm Diosynth, Samsung Biologics, Catalent, Boehringer Ingelheim

Between 2025 and 2030, the contract pharmaceutical fermentation services market is projected to expand from USD 16.0 billion to USD 23.5 billion, resulting in a value increase of USD 7.5 billion, which represents 40.3% of the total forecast growth for the decade.

This phase of development will be shaped by increasing biopharmaceutical pipeline expansion, rising outsourcing adoption, and growing demand for specialized manufacturing capabilities in drug development operations. Service providers are expanding their production capabilities to address the growing demand for scalable manufacturing solutions and enhanced regulatory compliance.

Contract Pharmaceutical Fermentation Services Market Key Takeaways

Metric	Value
Estimated Value in (2025E)	USD 16.0 billion
Forecast Value in (2035F)	USD 34.6 billion
Forecast CAGR (2025 to 2035)	7.8%

From 2030 to 2035, the market is forecast to grow from USD 23.5 billion to USD 34.6 billion, adding another USD 11.1 billion, which constitutes 59.7% of the overall ten-year expansion. This period is expected to be characterized by the expansion of advanced manufacturing systems, the integration of cutting-edge biotechnology platforms, and the development of enhanced production capabilities for major pharmaceutical companies.

The growing adoption of biologics development programs and efficient manufacturing outsourcing will drive demand for contract fermentation services with enhanced quality standards and improved production scalability.

Between 2020 and 2025, the contract pharmaceutical fermentation services market experienced robust recovery growth, driven by increasing biopharmaceutical development demand and growing recognition of outsourcing as essential strategy for drug manufacturing and development cost optimization.

The market developed as pharmaceutical companies recognized the potential for specialized service providers to enhance production capabilities while maintaining regulatory compliance and improving development timelines.

Technological advancement in fermentation systems and manufacturing processes began emphasizing the critical importance of maintaining product quality and operational efficiency in pharmaceutical production operations.

Why is the Contract Pharmaceutical Fermentation Services Market Growing?

Market expansion is being supported by the increasing global biopharmaceutical development and the corresponding need for specialized manufacturing services that can provide regulatory compliance while supporting diverse drug development applications across various pharmaceutical environments.

Modern pharmaceutical companies are increasingly focused on implementing outsourcing strategies that can reduce capital investment, accelerate development timelines, and provide consistent manufacturing performance in drug production operations. Contract fermentation services' proven ability to deliver manufacturing expertise, regulatory compliance, and scalable production capabilities make them essential partners for contemporary pharmaceutical development operations and commercial manufacturing solutions.

The growing emphasis on biologics development and manufacturing outsourcing is driving demand for contract services that can support complex production requirements, provide specialized expertise, and enable efficient manufacturing operations across varying pharmaceutical development configurations.

Pharmaceutical company preference for partners that combine technical expertise with regulatory compliance and production scalability is creating opportunities for innovative service implementations. The rising influence of biopharmaceutical innovation and development cost pressures is also contributing to increased adoption of contract fermentation services that can provide advanced manufacturing capabilities without compromising quality standards or regulatory compliance.

Opportunity Pathways - Contract Pharmaceutical Fermentation Services Market

The contract pharmaceutical fermentation services market is poised for robust growth and transformation. As pharmaceutical companies across both developed and emerging markets seek manufacturing partners that are experienced, compliant, scalable, and cost-effective, contract fermentation service providers are gaining prominence not just as manufacturing suppliers but as strategic partners for development acceleration, cost optimization, regulatory compliance, and production scaling.

Rising biopharmaceutical development and outsourcing trends in North America, Europe, and Asia Pacific amplify demand, while service providers are picking up on innovations in manufacturing technologies and capacity enhancement methods.

Pathways like advanced manufacturing systems, specialized capabilities, and integrated services promise strong margin uplift, especially in developed markets. Geographic expansion and capability diversification will capture volume, particularly where biopharmaceutical development is growing or manufacturing infrastructure requires enhancement. Quality pressures around regulatory compliance, manufacturing efficiency, technical expertise, and production scalability give structural support.

• Pathway A -- Advanced Manufacturing & Technology Systems. Pharmaceutical companies increasingly require services that offer cutting-edge manufacturing capabilities and specialized technologies. Service providers who invest in advanced manufacturing or enhance technology capabilities can command premium pricing. Expected revenue pool: USD 3,456.0-4,147.0 million
• Pathway B -- Integrated Development & Manufacturing Services. Comprehensive service systems -- development support, regulatory guidance, manufacturing integration -- improve client outcomes and development efficiency. Opportunity: USD 2,765.0-3,341.0 million
• Pathway C -- Specialized Biologics & Complex Molecules. Direct focus on biologics manufacturing, complex molecule production, and specialized therapeutic areas optimize service positioning and enhance client relationships. Systems with specialized capabilities will allow premium positioning. Revenue lift: USD 2,160.0-2,765.0 million
• Pathway D -- Commercial Scale Manufacturing. Extending capabilities into large-scale commercial production, supply chain management, and global manufacturing networks. Pharmaceutical companies seek partners who provide comprehensive, scalable solutions. Pool: USD 1,958.0-2,563.0 million
• Pathway E -- Emerging Market Expansion. Strong growth in developing pharmaceutical markets, biotechnology development, and manufacturing outsourcing. Local partnerships and manufacturing facilities help market penetration. Expected upside: USD 1,728.0-2,160.0 million
• Pathway F -- Regulatory & Quality Services. Compliance services, regulatory support, and quality assurance help pharmaceutical companies ensure product approval and manufacturing standards. Service approaches benefit from long-term partnerships. USD 1,210.0-1,555.0 million
• Pathway G -- Process Development & Optimization. Manufacturing efficiency, process innovation, and production optimization create competitive advantages and cost benefits. Pool: USD 1,037.0-1,382.0 million

Segmental Analysis

The market is segmented by scale, modality, and host. By scale, the market is divided into commercial GMP, clinical, and preclinical. By modality, it covers recombinant proteins, vaccines, and plasmids/others. By host, it is segmented into microbial, mammalian perfusion, and yeast/others. Regionally, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

By Scale, the Commercial GMP Segment Accounts for 52.0% Market Share

The commercial GMP scale is projected to account for 52.0% of the contract pharmaceutical fermentation services market in 2025, reaffirming its position as the leading scale category. Pharmaceutical companies increasingly utilize commercial GMP services for their established regulatory compliance, proven production capabilities, and reliable manufacturing scalability across drug commercialization, large-scale production, and supply chain applications.

Commercial GMP scale's established manufacturing procedures and consistent quality output directly address the industry requirements for reliable commercial supply and regulatory compliance in diverse pharmaceutical environments.

This scale segment forms the foundation of current market operations, as it represents the production level with the greatest revenue generation and established manufacturing infrastructure across multiple therapeutic areas and production scenarios. Service provider investments in enhanced manufacturing methods and capacity expansion continue to strengthen adoption among pharmaceutical companies.

With companies prioritizing commercial readiness and regulatory compliance, commercial GMP operations align with both quality objectives and business requirements, making them the central component of comprehensive contract manufacturing strategies.

By Modality, the Recombinant Proteins Segment Accounts for 44.0% Market Share

Recombinant proteins modality is projected to represent 44.0% of contract fermentation services demand in 2025, underscoring its critical role as the primary therapeutic requirement for biologics development and protein-based drug manufacturing.

Pharmaceutical companies prefer recombinant protein services for their therapeutic versatility, established production methods, and ability to provide diverse applications while supporting drug development and commercial manufacturing requirements. Positioned as essential modality for modern biopharmaceutical production, recombinant proteins offer both therapeutic advantages and manufacturing benefits.

The segment is supported by continuous innovation in protein expression and the growing availability of specialized production methods that enable diverse therapeutic applications with enhanced manufacturing capabilities. Service providers are investing in platform optimization to support therapeutic diversity and production efficiency delivery.

As biologics development becomes more prevalent and protein therapeutic requirements increase, recombinant proteins will continue to dominate the modality market while supporting advanced therapeutic positioning and manufacturing efficiency strategies.

By Host, the Microbial Segment Accounts for 61.0% Market Share

Microbial host systems are projected to represent 61.0% of contract fermentation services in 2025, underscoring their critical role as the primary production requirement for cost-effective manufacturing and scalable production operations.

Pharmaceutical companies prefer microbial systems for their production efficiency, cost-effectiveness, and ability to provide consistent quality while supporting manufacturing scalability and cost optimization requirements. Positioned as essential host system for modern pharmaceutical manufacturing, microbial systems offer both cost advantages and production benefits.

The segment is supported by continuous innovation in microbial expression and the growing availability of specialized host methods that enable enhanced production with improved manufacturing capabilities. Additionally, service providers are investing in system optimization to support production efficiency and cost-effectiveness delivery.

As pharmaceutical manufacturing becomes more cost-conscious and production efficiency requirements increase, microbial systems will continue to dominate the host market while supporting advanced manufacturing efficiency and cost optimization strategies.

What are the Drivers, Restraints, and Key Trends of the Contract Pharmaceutical Fermentation Services Market?

The contract pharmaceutical fermentation services market is advancing rapidly due to increasing biopharmaceutical development and growing adoption of manufacturing outsourcing that provides specialized expertise and cost optimization across diverse pharmaceutical applications.

However, the market faces challenges, including regulatory complexity, capacity constraints, and varying quality requirements across different therapeutic environments. Innovation in manufacturing technologies and regulatory expertise continues to influence service development and market expansion patterns.

Rising Biopharmaceutical Development and Outsourcing Trends

The growing expansion of biologics development and pharmaceutical outsourcing is enabling service providers to develop contract fermentation services that provide superior manufacturing expertise, enhanced regulatory compliance, and scalable production capacity in pharmaceutical environments.

Advanced manufacturing systems provide improved production capabilities while allowing more effective cost optimization and consistent quality delivery across various therapeutic areas and development requirements. Service providers are increasingly recognizing the competitive advantages of specialized manufacturing capabilities for market positioning and pharmaceutical industry targeting.

Manufacturing Innovation and Regulatory Excellence Drive Service Development

Modern contract fermentation service providers are incorporating advanced manufacturing methods and regulatory systems to enhance production capabilities, improve compliance efficiency, and ensure consistent quality delivery to pharmaceutical companies. These technologies improve manufacturing standards while enabling new capabilities, including complex molecule production and specialized therapeutic applications. Advanced manufacturing integration also allows service providers to support premium service positioning and production optimization beyond traditional manufacturing outsourcing.

Analysis of the Contract Pharmaceutical Fermentation Services Market by Key Countries

Country	CAGR (2025-2035)
USA	8.6%
Mexico	8.2%
Germany	7.8%
France	7.7%
UK	7.5%
South Korea	7.4%
Japan	7.2%

The contract pharmaceutical fermentation services market is experiencing robust growth globally, with the USA leading at an 8.6% CAGR through 2035, driven by extensive biopharmaceutical development, advanced manufacturing infrastructure investments, and significant adoption of outsourcing strategies. Mexico follows at 8.2%, supported by growing pharmaceutical development, rapid manufacturing modernization, and growing adoption of contract manufacturing systems.

Germany shows growth at 7.8%, emphasizing quality standards and regulatory capabilities. France and UK record strong growth, focusing on pharmaceutical development and manufacturing optimization. South Korea demonstrates 7.4% growth, supported by biotechnology trends and manufacturing expansion. Japan demonstrates 7.2% growth, supported by advanced capabilities but facing competitive pressures.

The report covers an in-depth analysis of 40+ countries; seven top-performing countries are highlighted below.

United States Demonstrates Biopharmaceutical Innovation

The U.S. market emphasizes advanced manufacturing features, including precision production control and integration with comprehensive pharmaceutical platforms that manage development optimization, regulatory compliance, and quality applications through unified manufacturing systems. The country demonstrates strong growth at 8.6% CAGR, driven by biopharmaceutical innovation, regulatory excellence, and emerging complex therapeutic applications that support manufacturing system integration.

American pharmaceutical companies prioritize manufacturing effectiveness with contract fermentation services delivering consistent production performance through advanced manufacturing capabilities and specialized regulatory adaptation.

Technology deployment channels include major pharmaceutical companies, specialized biotechnology firms, and development organizations that support professional applications for complex drug manufacturing and therapeutic production applications.

Pharmaceutical platform integration capabilities with established development systems expand market appeal across diverse manufacturing requirements seeking production benefits and regulatory compliance. The resilient biopharmaceutical sector and expanding development capacity additions create sustained demand, while innovative applications in personalized medicine open new growth avenues.

Performance Metrics:

• Biopharmaceutical facilities in Massachusetts, California, and New Jersey leading contract fermentation adoption for drug manufacturing applications
• Specialized pharmaceutical service channels maintaining 76% market share for complex manufacturing integration applications
• Development programs supporting 45% of service acquisitions across pharmaceutical and biotechnology facilities
• Pharmaceutical platform compatibility with major development systems driving procurement selection criteria

Mexico Maintains Manufacturing Growth

Mexico's expanding pharmaceutical market demonstrates sophisticated contract fermentation adoption with documented manufacturing effectiveness in drug production applications and pharmaceutical facilities through integration with existing manufacturing systems and pharmaceutical infrastructure. The country leverages growing pharmaceutical development and manufacturing integration to maintain strong growth at 8.2% CAGR. Manufacturing centers, including Mexico City, Guadalajara, and Tijuana, showcase premium applications where service systems integrate with comprehensive pharmaceutical platforms and production management systems to optimize manufacturing and regulatory effectiveness.

Mexican pharmaceutical companies prioritize cost optimization and regulatory quality in contract fermentation development, creating demand for premium service systems with advanced features, including regulatory compliance integration and pharmaceutical manufacturing systems.

The market benefits from established pharmaceutical infrastructure and a willingness to invest in manufacturing technologies that provide long-term production benefits and compliance with international pharmaceutical and regulatory standards. Premium manufacturing applications, pharmaceutical production systems, and development programs drive diversified demand across multiple therapeutic segments.

Market Intelligence Brief:

• Pharmaceutical market focuses on cost optimization and regulatory quality compliance, driving premium segment growth
• Manufacturing partnerships providing 46% faster development cycles
• Technology collaboration between Mexican pharmaceutical companies and international service providers
• Regulatory training programs expanding contract fermentation system integration in pharmaceutical and manufacturing scenarios

Germany Emphasizes Manufacturing Excellence

Germany demonstrates steady market development with a 7.8% CAGR, distinguished by pharmaceutical companies' preference for high-quality contract fermentation services that integrate seamlessly with existing development systems and provide reliable long-term manufacturing performance in specialized pharmaceutical applications.

The market prioritizes advanced features, including precision manufacturing control, regulatory durability, and integration with comprehensive pharmaceutical platforms that reflect German industry expectations for technological sophistication and operational excellence.

Growth drivers encompass pharmaceutical manufacturing optimization applications, expanding development requirements, and advanced production system integration. German companies emphasize quality control systems and comprehensive regulatory documentation that align with domestic pharmaceutical standards.

The convergence of advanced manufacturing technology, pharmaceutical industry presence, and traditional quality heritage creates diversified demand across multiple therapeutic segments.

Market Characteristics:

• Premium focus on commercial GMP systems with advanced manufacturing capabilities and precision regulatory features
• Integration requirements with existing pharmaceutical development and manufacturing platforms
• Emphasis on manufacturing reliability and long-term regulatory compliance in pharmaceutical applications

France Shows Pharmaceutical Development

France demonstrates steady expansion at 7.7% CAGR through diversified demand from pharmaceutical programs, biotechnology activities, and specialty manufacturing projects. Major pharmaceutical hubs in regions throughout the country drive contract fermentation adoption for pharmaceutical and specialty manufacturing production.

Pharmaceutical heritage and biotechnology programs create sustained market demand, while specialty and advanced applications provide additional growth opportunities. Company preference for manufacturing services and pharmaceutical sophistication supports consistent market development.

Market Characteristics:

• Strong pharmaceutical heritage and established biotechnology culture supporting premium positioning
• Advanced specialty manufacturing and pharmaceutical sectors driving demand for high-quality contract services
• Pharmaceutical positioning capabilities and biotechnology market presence supporting diversified revenue streams

United Kingdom Demonstrates Manufacturing Innovation

The U.K. market maintains strong growth at 7.5% CAGR, driven by pharmaceutical modernization, biotechnology development, and specialty manufacturing applications. British pharmaceutical facilities and biotechnology companies are implementing advanced contract fermentation systems to enhance manufacturing capabilities and support development operations that align with pharmaceutical regulations and quality standards.

Market expansion benefits from pharmaceutical programs that mandate manufacturing performance capabilities in drug development specifications, creating sustained demand where production flexibility and regulatory compliance represent critical requirements.

Strategic Market Indicators:

• Pharmaceutical and biotechnology facilities leading adoption with manufacturing modernization programs requiring advanced contract fermentation systems
• Pharmaceutical programs providing regulatory support for advanced manufacturing system acquisition
• Regulatory compliance requirements driving demand for certified systems with pharmaceutical operational compatibility
• Specialized biotechnology and pharmaceutical segments adopting comprehensive contract fermentation solutions for manufacturing optimization

Japan Shows Technology-Focused Development

Japan maintains steady expansion at 7.2% CAGR, distinguished by pharmaceutical companies' preference for high-quality contract fermentation services that integrate seamlessly with existing manufacturing systems and provide reliable long-term production performance in specialized pharmaceutical applications.

The market prioritizes advanced features, including precision manufacturing control, regulatory quality, and integration with comprehensive pharmaceutical platforms that reflect Japanese industry expectations for technological sophistication and manufacturing excellence.

High-specification pharmaceutical and biotechnology applications drive demand, supported by advanced manufacturing research and development initiatives. Japanese companies emphasize service quality, consistent performance characteristics, and comprehensive regulatory documentation that aligns with stringent pharmaceutical standards. The focus on advanced applications and technological excellence supports stable growth despite competitive market conditions.

Market Characteristics:

• Technology focus on microbial systems with advanced manufacturing capabilities and precision regulatory features
• Integration requirements with existing pharmaceutical and biotechnology platforms
• Emphasis on manufacturing reliability and long-term regulatory compliance in pharmaceutical applications

South Korea Emphasizes Biotechnology Innovation

South Korea maintains robust development at 7.4% CAGR through biotechnology expansion, pharmaceutical growth, and manufacturing applications. Korean biotechnology facilities and pharmaceutical companies are implementing advanced contract fermentation systems to enhance manufacturing capabilities and support development operations that align with pharmaceutical regulations and quality standards.

Market expansion benefits from government biotechnology programs that mandate manufacturing performance capabilities in pharmaceutical specifications, creating sustained demand where production flexibility and regulatory compliance represent critical requirements.

Strategic Market Indicators:

• Biotechnology and pharmaceutical facilities leading adoption with manufacturing modernization programs requiring advanced contract fermentation systems
• Government biotechnology programs providing regulatory support for advanced manufacturing system acquisition
• Regulatory compliance requirements driving demand for certified systems with international pharmaceutical compatibility
• Specialized pharmaceutical and biotechnology segments adopting comprehensive contract fermentation solutions for manufacturing optimization

Europe Market Split by Countries

The contract pharmaceutical fermentation services market in Europe is projected to grow from USD 4.80 billion in 2025 to USD 10.38 billion by 2035, registering a CAGR of 7.8% over the forecast period. Germany is expected to maintain its leadership position with a 29.6% market share in 2025, increasing to 30.1% by 2035, supported by its advanced pharmaceutical infrastructure, comprehensive biotechnology capabilities, and major manufacturing facilities serving European and international markets.

France follows with a 24.3% share in 2025, projected to reach 24.7% by 2035, driven by established pharmaceutical heritage, biotechnology programs, and manufacturing sophistication, supported by growing contract services trends. United Kingdom holds a 21.9% share in 2025, expected to reach 22.3% by 2035, supported by pharmaceutical modernization and biotechnology development. Netherlands commands a 12.7% share in 2025, projected to reach 12.4% by 2035, while Spain accounts for 8.1% in 2025, expected to reach 7.9% by 2035.

The Rest of Europe region is anticipated to maintain momentum, with its collective share from 3.4% to 2.6% by 2035, attributed to increasing pharmaceutical development across Eastern European countries and growing contract manufacturing across various European markets implementing biotechnology programs.

Competitive Landscape of the Contract Pharmaceutical Fermentation Services Market

The contract pharmaceutical fermentation services market is characterized by competition among established contract manufacturing organizations, specialized biotechnology service providers, and integrated pharmaceutical service companies.

Companies are investing in advanced manufacturing research, capacity expansion, regulatory excellence, and comprehensive service portfolios to deliver reliable, compliant, and scalable contract fermentation solutions. Innovation in manufacturing technologies, regulatory capabilities, and service integration is central to strengthening market position and competitive advantage.

Lonza leads the market with a 12.0% market share, offering specialized manufacturing services with a focus on regulatory compliance and advanced production capabilities for pharmaceutical industry operations.

Thermo Fisher (Patheon) provides comprehensive manufacturing portfolios with an emphasis on integrated services, technological innovation, and global manufacturing networks. Fujifilm Diosynth delivers diverse biotechnology services with a focus on biologics manufacturing and specialized therapeutic capabilities. Samsung Biologics specializes in large-scale manufacturing with emphasis on capacity leadership and cost optimization.

Catalent focuses on integrated pharmaceutical services with drug development support and manufacturing capabilities. Boehringer Ingelheim offers biopharmaceutical manufacturing with emphasis on European leadership and regulatory expertise. WuXi Biologics provides comprehensive services with Asian market positioning and rapid capacity expansion.

The competitive landscape is evolving as companies invest in advanced manufacturing technologies, specialized capabilities, and global expansion strategies. Market leaders are differentiating through manufacturing expertise, regulatory compliance excellence, and comprehensive service platforms.

Innovation in manufacturing efficiency, capacity expansion, and service integration drives competitive positioning, while strategic partnerships with pharmaceutical companies and biotechnology firms support market expansion and capability development initiatives.

Key Players in the Contract Pharmaceutical Fermentation Services Market

• Lonza Group AG
• Thermo Fisher Scientific Inc. (Patheon)
• Fujifilm Diosynth Biotechnologies
• Samsung Biologics Co., Ltd.
• Catalent, Inc.
• Boehringer Ingelheim GmbH
• WuXi Biologics (Cayman) Inc.
• AGC Biologics
• Novasep Holding SAS
• Rentschler Biopharma SE

Scope of the Report

Items	Values
Quantitative Units (2025)	USD 16.0 Billion
Scale	Commercial GMP, Clinical, Preclinical
Modality	Recombinant proteins, Vaccines, Plasmids/others
Host	Microbial, Mammalian perfusion, Yeast/others
Regions Covered	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Countries Covered	United States, Canada, Germany, United Kingdom, France, Japan, South Korea, Mexico, China and 40+ countries
Key Companies Profiled	Lonza, Thermo Fisher, Fujifilm Diosynth, Samsung Biologics, Catalent, Boehringer Ingelheim, and WuXi Biologics
Additional Attributes	Revenue by scale and modality category, regional demand trends, competitive landscape, technological advancements in manufacturing systems, capacity development, regulatory innovation, and service optimization

Contract Pharmaceutical Fermentation Services Market by Segments

Scale:

• Commercial GMP
• Clinical
• Preclinical

Modality:

• Recombinant proteins
• Vaccines
• Plasmids/others

Host:

• Microbial
• Mammalian perfusion
• Yeast/others

Region:

North America

• United States
• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Nordic
• BENELUX
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Latin America

• Brazil
• Chile
• Rest of Latin America

Middle East & Africa

• Kingdom of Saudi Arabia
• Other GCC Countries
• Turkey
• South Africa
• Other African Union
• Rest of Middle East & Africa